IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10821104 B1

PDFFull Text
Date of Patent:
Nov. 03, 2020

Filed:

Dec. 07, 2016

Five-membered heterocyclic amides wnt pathway inhibitor

Applicant:

Suzhou Sinovent Pharmaceuticals Co., Ltd., Jiangsu, CN;

Inventors:

Yonghui Wang, Zhejiang, CN;

Yan Zhu, Zhejiang, CN;

Juan Zhou, Zhejiang, CN;

Yujun Gao, Zhejiang, CN;

Shiqun Wang, Zhejiang, CN;

Dong Wang, Zhejiang, CN;

Wandeng Liu, Zhejiang, CN;

Ximing Shen, Zhejiang, CN;

Binbin Hong, Zhejiang, CN;

Tao Liu, Zhejiang, CN;

Yaodong Wu, Zhejiang, CN;

Chunqi Li, Zhejiang, CN;

Assignee:

Suzhou Sinovent Pharmaceuticals Co., Ltd., Jiangsu, CN;

Attorney:

Muncy, Geissler, Olds & Lowe, P.C.

Primary Examiner:

Brian E McDowell

Int. Cl.
CPC ...
C07D 401/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); A61K 31/444 (2006.01); A61K 31/497 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 401/12 (2006.01); A61P 35/00 (2006.01); A61K 31/4427 (2006.01); A61K 31/506 (2006.01);
U.S. Cl.
CPC ...
A61K 31/444 (2013.01); A61K 31/4427 (2013.01); A61K 31/497 (2013.01); A61K 31/506 (2013.01); A61P 35/00 (2018.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01);
Abstract

A five-membered heterocyclic amide WNT pathway inhibitor having the following general structural formula: The five-membered heterocyclic amide WNT pathway inhibitor has a remarkable anti-tumor activity based on a target-based rational drug design, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.

Find Patent Forward Citations

Loading…